Table 1.

Baseline characteristics.

CharacteristicThird TNF-blocking Agent, n = 64Rituximab, n = 90p
Female (%)46/64 (72)66/90 (73)NS
Age, yrs, mean (SD)53.3 (12.9)56.6 (12.2)NS
Disease duration, yrs, median (IQR)8.9 (9.2)10.9 (13.7)NS
Rheumatoid factor-positive (%)51/64 (80)69/90 (77)NS
No. previous DMARD, median (IQR)4.0 (2.0)4.0 (2.3)NS
DAS28, mean (SD)*5.1 (1.30)5.32 (1.25)NS
  SJC28, mean (SD)9.4 (6.5)8.7 (5.8)NS
  TJC28, mean (SD)9.0 (7.5)8.0 (6.3)NS
  ESR, mm/h, median (IQR)26.0 (29.5)31.0 (28.5)0.049
  CRP, mg/l, median (IQR)10.0 (24.5)16.0 (38.0)NS
  VASGH, mean (SD)57.5 (26.9)60.8 (19.1)NS
HAQ, mean (SD)**1.51 (0.64)1.52 (0.78)NS
First TNF-blocking agent
  Infliximab (%)31 (48)38 (42)NS
  Etanercept (%)9 (14)32 (36)0.003
  Adalimumab (%)24 (38)20 (22)0.039
Second TNF-blocking agent
  Infliximab (%)12 (19)6 (7)0.021
  Etanercept (%)33 (52)40 (44)NS
  Adalimumab (%)19 (29)44 (49)0.017
Third TNF-blocking agent
  Infliximab (%)21 (33)
  Etanercept (%)22 (34)
  Adalimumab (%)21 (33)
Concomitant therapy
  MTX (%)34/64 (53)42/86 (49)NS
  Other DMARD (%)20/64 (31)19/86 (22)NS
  Oral corticosteroids (%)24/64 (38)38/86 (44)NS
  • * DAS28, SJC28, TJC28, and ESR were missing in 17% (11/64), CRP was missing in 23% (15/64), and VASGH was missing in 36% (23/64) of patients receiving a third TNF-blocking agent. DAS28, SJC28, TJC28, and ESR were missing in 10% (9/90), CRP was missing in 12% (11/90), and VASGH was missing in 12% (11/90) of patients receiving rituximab.

  • ** Missing in 34% (22/64) of patients receiving a third TNF-blocking agent and in 19% (17/90) of patients receiving rituximab. DMARD: disease-modifying antirheumatic drug; IQR: interquartile range; DAS28: Disease Activity Score on 28 joints; SJC: swollen joint count; TJC: tender joint count; ESR: erythrocyte sedimentation rate; CRP: C-reactive protein; VASHG: visual analog scale for general health; HAQ: Health Assessment Questionnaire; TNF: tumor necrosis factor; MTX: methotrexate.